NRX Pharmaceuticals

NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NRx Pharmaceuticals reports strong Q1 performance and growth opportunities

NRx Pharmaceuticals made strides in innovation, debt reduction, and financial stability in Q1 2024.
The company's focus on mental health treatments and addressing unmet medical needs shows market relevance.
Challenges include resolving short interest concerns and securing FDA approvals for key drugs.
Opportunities lie in out-licensing, revenue generation, and partnerships for growth and market expansion.

NRx Pharmaceuticals reports progress in financials and scientific breakthroughs

NRx Pharmaceuticals showcased financial and scientific progress, positioning itself for growth and market penetration.
Strategic initiatives like clinic roll-up and commercial targeting demonstrate a proactive approach to market challenges.
While facing transitions and competition, NRx Pharmaceuticals has opportunities for expansion and innovation in psychiatric treatments.
The company's focus on financial stability, product development, and market strategies reflects a comprehensive growth strategy.

NRx Pharmaceuticals reports improved financials and plans for growth

NRx Pharmaceuticals demonstrated improved financial performance and strategic planning in Q3 2024, with reduced losses and enhanced operational efficiency.
The company's focus on innovation, acquisitions, and precision psychiatry clinics highlights a commitment to growth and market leadership.
While facing challenges in revenue recognition and clinic valuations, NRx Pharmaceuticals has opportunities to drive revenue growth and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NRx Pharmaceuticals (NASDAQ: NRXP) has completed an analysis in the subgroup of Zyesami and placebo-treated patients previously treated with Gilead Science Inc's (NASDAQ: GILD) remdesivir in the COVID-AIV trial representing approximately 70% of the study population. The analysis indicates a substantial improvement after Zyesami (aviptadil) treatment in patients with critical COVID-19 and Respiratory Failure over existing therapies.

Why Are NRx Pharma's Shares Soaring Premarket?

RADNOR, Pa., Nov. 29, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP) announced today that it has completed an analysis to identify clinical evidence that indicates a substantial improvement after treatment with ZYESAMI® (aviptadil) in patients with Critical COVID-19 and Respiratory Failure over existing therapies such as remdesivir. NRx asked Prof. David Schoenfeld, one of the world's most widely published statisticians with unique expertise in life-threatening diseases of the lung to conduct the analysis.

NRx Pharmaceuticals Identifies Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in ZYESAMI® (aviptadil) Treated Patients Previously Administered Remdesivir

Israel Institute for Biological Research (IIBR) has posted scientific results from an initial sample of Phase 2 vaccinated patients to assess the BriLife vaccine against the COVID-19 Delta variant. Blood (Sera) from an initial sample of 11 trial participants demonstrated effective neutralizing antibodies against the original "wild-type" virus and was tested for antibodies to the Delta variant.

NRx Pharma Skyrockets After BriLife COVID-19 Vaccine Data Against Delta Variant

RADNOR, Pa., Nov. 26, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ: NRXP), today notes that the Israel Institute for Biological Research (IIBR) has posted scientific results from an initial sample of phase 2 vaccinated patients in order to assess the potential effectiveness of the BriLife® vaccine against the Delta variant of the SARS-CoV-2 virus. Blood (Sera) from an initial sample of 11 trial participants demonstrated effective neutralizing antibodies against the original “wild-type” Coronavirus and was tested for antibodies to the Delta variant. Of the eleven tested samples, ten were found to neutralize the Delta variant1. The antibody levels are displayed in the scientific manuscript.

NRx Pharmaceuticals Notes New Data on BriLife® COVID-19 Vaccine Effectiveness Against Delta Variant Posted by Israel Institute for Biological Research

Relief Therapeutics Holding SA's (OTC: RLFTF) collaborating partner NRx Pharmaceuticals Inc (NASDAQ: NRXP) has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.  NRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.

FDA Denies Breakthrough Tag For NRx Pharma's COVID-19 Candidate

NRx Pharmaceuticals, Inc. (NRXP) CEO Jonathan Javitt on Q3 2021 Results - Earnings Call Transcript

RADNOR, Pa., Nov. 16, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical-stage, biopharmaceutical company, today provided a business update and financial results for the quarter ended September 30, 2021. NRx will host a conference call Tuesday morning, November 16th, at 8:30 AM Eastern Time to discuss its business update and third-quarter financial results.

NRx Pharmaceuticals Reports Third-Quarter 2021 Business Update and Financial Results

Conference Begins on November 15, 2021 Conference Begins on November 15, 2021

NRx Pharmaceutical's Chairman and Chief Executive Officer Jonathan Javitt to Present Company Business Update at H.C. Wainwright 7th Annual Israel Conference

NRx Pharmaceuticals Inc (NASDAQ: NRXP) has received the FDA's response to NRx's submission of updated manufacturing information for Zyesami (aviptadil). The completion of this review, without the imposition of any clinical hold by the FDA, enables NRx to distribute Zyesami for clinical trials and other future purposes approved in future regulatory actions.

NRx Pharma's COVID-19 Candidate Receives FDA Review For Manufacturing Information

The company received good news from the FDA.

Why NRX Pharmaceuticals Stock Is Jumping Today

RADNOR, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (NASDAQ:  NRXP ), today announced receipt of the US Food and Drug Administration's (FDA) response to NRx's October 8 submission of updated manufacturing information for ZYESAMI® (aviptadil).

NRx Pharmaceuticals Receives US Food and Drug Administration Review of ZYESAMI® (aviptadil) Manufacturing Information

--Company to Host Conference Call on Tuesday, November 16, 2021, at 8:30AM ET-- --Company to Host Conference Call on Tuesday, November 16, 2021, at 8:30AM ET--

NRx Pharmaceuticals to Report Third Quarter 2021 Financial and Business Update on Tuesday, November 16, 2021

New York, New York--(Newsfile Corp. - November 8, 2021) - Pomerantz LLP is investigating claims on behalf of investors of NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ: NRXP). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether NRx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NRx Pharmaceuticals, Inc. - NRXP

The FDA has declined the emergency use authorization (EUA) for NRx Pharmaceuticals' (NASDAQ: NRXP) Zyesami (aviptadil).  The Company is developing aviptadil in collaboration with Relief Therapeutics Holding SA (OTC: RLFTF).

NRx Pharma Stock Nosedives As FDA Strikes Off Its COVID-19 Drug Hopeful

RADNOR, Pa., Nov. 5, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NASDAQ: NRXP), via its subsidiary, NRx Luxembourg (NRx), has concluded a business mission to Luxembourg at the invitation of the Luxembourg Ministry of the Economy in preparation for the establishment of vaccine manufacturing capability to serve European and adjacent markets.

NRx Pharmaceuticals Initiates Senior Level Finance and Business Initiatives with Luxembourg Ministry of the Economy, BNP Paribas, and Vaccine Manufacturing Partners for BriLife® COVID-19 Vaccine Production

GENEVA, SWITZERLAND / ACCESSWIRE / November 5, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals, Inc., (Nasdaq: NRXP) ("NRx"), has issued a press release announcing that it was declined Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the use of IV aviptadil for the treatment of acute respiratory failure due to critical COVID-19. The related NRx press release can be accessed through the following link.

Relief Reports U.S. Collaboration Partner's Emergency Use Authorization Request for ZYESAMI/RLF-100 (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure was Declined by U.S. FDA

RADNOR, Pa., Nov. 4, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company (NRx), today announced that the US Food and Drug Administration (FDA) has declined to issue an Emergency Use Authorization (EUA) for ZYESAMI® (aviptadil).

US Food and Drug Administration Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for Patients with Critical COVID-19 with Respiratory Failure

RADNOR, Pa., Nov. 2, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, today provided a new safety update on ZYESAMI® (aviptadil), which is being tested in the ACTIV-3b Critical Care Phase 3 study sponsored by the National Institutes of Health.

NRx Pharmaceuticals Announces Favorable, New Safety Report for ZYESAMI® (aviptadil) in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19

This company's coronavirus efforts could pay off big time.

1 Small-Cap Stock With 10X Potential

Jasper Therapeutics

These two tiny drugmakers could make early shareholders wealthy.

2 Biotech Stocks Poised for Jaw-Dropping Growth

The drugmaker is being sued by Relief Therapeutics.

Why NRx Pharmaceuticals Stock Is Tumbling Today

GENEVA, SWITZERLAND / ACCESSWIRE / October 15, 2021 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (" NRx "), has issued a press release announcing that the peer-reviewed Journal of Infectious Diseases and Treatment has published positive trial data from a prospective, open label, administratively controlled trial of aviptadil in high comorbidity patients suffering from critical COVID-19 with respiratory failure. According to the press release, the study reported 60-day survival in 81% of those treated with aviptadil, compared to 21% survival among those who received standard of care treatment at the Houston Methodist Hospital (P

Relief Reports U.S. Collaboration Partner Announces Journal of Infectious Diseases and Treatment Publishes Positive Aviptadil Data in High Comorbidity Critical COVID-19 Patients w/ Respiratory Failure

NRx Pharmaceuticals Inc (NASDAQ:NRXP) burst onto the scene today, tacking on 35.3% to trade at $12.77 at last check, following the publication of peer-reviewed results from a controlled trial of NRx's drug, aviptadil.

Pharma Stock Rises After Upbeat Covid Treatment Data

New clinical trial results bode well for aviptadil in treating critically ill COVID-19 patients.

Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday

NRX Pharmaceuticals Inc (NASDAQ: NRXP) is trading significantly higher Thursday after the company announced the Journal of Infectious Diseases and Treatment published trial data of aviptadil in high comorbidity patients suffering from critical COVID-19 with respiratory failure. The study reported 60-day survival in 81% of those treated with aviptadil, compared to 21% survival among those who received standard of care treatment at the Houston Methodist Hospital.

News for NRX Pharmaceuticals Stock (NRXP)